Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: D03AX13Orphan Medicine

Filsuvez(dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w))

Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa, Junctional

Marketing Authorisation Holder: Chiesi Farmaceutici S.p.A

EMA Authorisation: 21/06/2022

INN: birch bark extract

Indication

Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Filsuvez — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.